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Tyrosine hydroxylase deficiency is an autosomal recessive disorder resulting from cerebral catecholamine deficiency. Tyrosine
hydroxylase deficiency has been reported in fewer than 40 patients worldwide. To recapitulate all available evidence on clinical
phenotypes and rational diagnostic and therapeutic approaches for this devastating, but treatable, neurometabolic disorder, we
studied 36 patients with tyrosine hydroxylase deficiency and reviewed the literature. Based on the presenting neurological
features, tyrosine hydroxylase deficiency can be divided in two phenotypes: an infantile onset, progressive, hypokinetic-rigid
syndrome with dystonia (type A), and a complex encephalopathy with neonatal onset (type B). Decreased cerebrospinal fluid
concentrations of homovanillic acid and 3-methoxy-4-hydroxyphenylethylene glycol, with normal 5-hydroxyindoleacetic acid
cerebrospinal fluid concentrations, are the biochemical hallmark of tyrosine hydroxylase deficiency. The homovanillic acid
concentrations and homovanillic acid/5-hydroxyindoleacetic acid ratio in cerebrospinal fluid correlate with the severity of the
phenotype. Tyrosine hydroxylase deficiency is almost exclusively caused by missense mutations in the TH gene and its promoter
region, suggesting that mutations with more deleterious effects on the protein are incompatible with life. Genotype–phenotype
correlations do not exist for the common c.698G4A and c.707T4C mutations. Carriership of at least one promotor mutation,
however, apparently predicts type A tyrosine hydroxylase deficiency. Most patients with tyrosine hydroxylase deficiency can be
successfully treated with L-dopa.
Keywords: tyrosine hydroxylase; neurotransmitters; cerebrospinal fluid; dystonia; L-dopa
Abbreviations: 5HIAA = 5-hydroxyindoleacetic acid; HVA = homovanillic acid; MHPG = 3-methoxy-4-hydroxyphenylethylene
glycol; THD = tyrosine hydroxylase deficiency
Introduction
The enzyme tyrosine hydroxylase (EC 1.14.16.2) catalyzes the
conversion of L-tyrosine to L-dihydroxyphenylalanine (L-dopa),
which is the rate-limiting step in the biosynthesis of the catechol-
amines dopamine, norepinephrine and epinephrine (Fig. 1).
Catecholamines are produced in the brain and adrenal medulla,
but also in non-neuronal, e.g. renal, intestinal and lymphoid
tissues. Their vital functions as neurotransmitters and hormones,
and the crucial role of tyrosine hydroxylase in their biosynthesis
are demonstrated by the observation that complete loss of tyrosine
hydroxylase activity is lethal in knock-out mice (Zhou et al., 1995).
Human tyrosine hydroxylase deficiency [THD; Online Mendelian
Inheritance in Man (OMIM) number 191290] is an autosomal
recessive neurometabolic disorder due to mutations in the tyrosine
hydroxylase (TH) gene on chromosome 11p15.5. The first reports
of THD described patients with an early onset, progressive
L-dopa-responsive dystonia (Castaigne et al., 1971; Rondot and
Ziegler, 1983; Rondot et al., 1992). Later, neonates were recog-
nized with a more severe phenotype described as progressive,
L-dopa-non-responsive encephalopathy (Hoffmann et al., 2003).
THD can be diagnosed by demonstrating decreased CSF levels
of the down-stream metabolites of the catecholamine degrad-
ation pathway (Fig. 1), i.e. homovanillic acid (HVA) and
3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and by mu-
tation analysis of the TH gene.
THD has been reported in fewer than 40 patients worldwide,
reviewed in this article. This disorder is known under different
names in the literature, namely ‘Segawa syndrome’, ‘infantile par-
kinsonism’ and ‘L-dopa-responsive dystonia’. ‘Segawa syndrome’,
however, is also used to indicate another defect in neurotransmit-
ter biosynthesis, caused by GTP cyclohydrolase I mutations.
‘Infantile parkinsonism’ and L-dopa-responsiveness are not found
in all patients with THD. Furthermore, the L-dopa-responsive dys-
tonias encompass a heterogeneous class of movement disorders,
THD being only one of them (Muller et al., 1998; Albanese et al.,
2006; Tarsy and Simon, 2006; Muller, 2009). Finally, the pheno-
type of THD can be so complex that it is not simply associated
with an extrapyramidal movement disorder (Hoffmann et al.,
2003). Altogether, we prefer to name the disorder after its under-
lying enzymatic defect, as is common practice for inborn errors of
metabolism.
In this article, we summarize the medical literature on human
THD, and include detailed novel clinical, biochemical and genetic
data on thus far unpublished patients. This large review on THD
recapitulates all available evidence on clinical phenotypes and ra-
tional diagnostic and therapeutic approaches of this severe, but
potentially treatable disorder.
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Methods
Our laboratory has a longstanding tradition of neurotransmitter ana-
lysis, and we have been performing TH gene mutation analysis since
the genetic basis of THD was elucidated. This history supplies us with a
unique database including patients with biochemically and genetically
proven THD from many different countries.
The laboratory methodologies used for CSF neurotransmitter
analysis have previously been reported in detail (Brautigam et al.,
1998; Verbeek et al., 2008) Reference values for HVA and
5-hydroxyindoleacetic acid (5HIAA; end-product of serotonin degrad-
ation) in CSF decrease with age, and there is a rostrocaudal gradient
for the concentrations of both metabolites, necessitating analysis of a
standardized CSF fraction (Brautigam et al., 1998) Mutation analysis
of the TH gene was performed as previously described (van den
Heuvel et al., 1998) Numbering of coding sequence mutations was
according to GenBank reference sequence NM_199292.1 (tyrosine
hydroxylase isoform A) in which the A of the ATG transcription initi-
ation codon is designated position 1. Mutations were named according
to the guidelines of the Human Genome Variation Society
(www.hgvs.org).
A questionnaire was sent to all physicians who have referred (sam-
ples from) THD patients to our centre. In this way we collected de-
tailed information on demographic data, pregnancy and perinatal
period, presenting clinical features, mode of treatment, follow-up
during treatment and results of cerebral imaging studies. The
results of CSF and mutation analysis were available in our database.
In those few patients in whom CSF analysis was performed elsewhere,
the results were obtained together with the appropriate reference
values.
A Pubmed search was performed for reports in English, using the
terms: ‘tyrosine hydroxylase recessive’ and ‘tyrosine hydroxylase dys-
tonia’. The reference lists of all relevant papers were checked for other
citations, especially those reports from the era before THD was recog-
nized as a separate disease entity.
This study was approved by the ethics committee of the Radboud
University Nijmegen Medical Centre, The Netherlands. The require-
ment for additional local ethical approval differed between participat-
ing countries and was obtained if required.
Results
We had the names of 36 patients with THD in our database.
Questionnaires were completed by the referring physicians of all
patients.
Literature
Besides reports concerning patients who had been diagnosed in
our laboratory (Table 1) (Castaigne et al., 1971; Rondot and
Ziegler, 1983; Rondot et al., 1992; van den Heuvel et al., 1998;
Brautigam et al., 1999; Wevers et al., 1999; de Lonlay et al.,
2000; de Rijk-Van Andel et al., 2000; Dionisi-Vici et al., 2000;
Janssen et al., 2000; Swaans et al., 2000; Haussler et al., 2001;
Grattan-Smith et al., 2002; Hoffmann et al., 2003; Schiller et al.,
2004; Verbeek et al., 2007; Zafeiriou et al., 2009), we only found
14 other THD patients from 12 families in whom the diagnosis
was genetically proven (Ludecke et al., 1995, 1996; Knappskog
Figure 1 Simplified scheme of the biosynthesis and catabolism of serotonin and the catecholamines dopamine, norepinephrine and
epinephrine. TPH = tryptophan hydroxylase; AADC = aromatic amino acid decarboxylase; PAH = phenylalanine hydroxylase; TH = tyrosine
hydroxylase; BH4 = tetrahydrobiopterin; DOPAC = 3,4-dihydroxyphenylacetic acid.
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et al., 1995; Surtees and Clayton, 1998; Furukawa et al., 2001;
Diepold et al., 2005; Moller et al., 2005; Yeung et al., 2006;
Giovanniello et al., 2007; Ribases et al., 2007; Wu et al., 2008;
Clot et al., 2009; Doummar et al., 2009). The key data on these
patients, and type A/B classification (see next paragraph) based on
available clinical descriptions, are summarized in Table 2.
Clinical features
After careful evaluation of the detailed case histories in the litera-
ture and the questionnaires used in this study, it was possible to
class the different phenotypes at presentation into two major
groups. Most patients (n= 25) suffered from a disorder that can
be summarized as a progressive hypokinetic-rigid syndrome with
dystonia. The onset of symptoms was generally in the first year of
life (age range: 2 months and 5 years). This is the first phenotype
described in the literature, further referred to as type A in this
article (Castaigne et al., 1971; Rondot and Ziegler, 1983;
Rondot et al., 1992; Knappskog et al., 1995; Ludecke et al.,
1995; Swaans et al., 2000; Furukawa et al., 2001; Diepold
et al., 2005; Yeung et al., 2006; Giovanniello et al., 2007;
Ribases et al., 2007; Wu et al., 2008; Clot et al., 2009). The
other eleven patients suffered from a more ‘complex encephalop-
athy’ with earlier onset (age range: 0–3 months), as described by
Hoffmann et al. (2003), designated type B. These two phenotypes
are defined in detail in Boxes 1 and 2. Although, we found no
difficulties in designating individual patients into type A or B THD,
it was obvious that the phenotype of THD is a spectrum with
overlap of clinical features between both groups. Patient 24,
previously described by Grattan-Smith et al. (2002), is a good
example of a type A patient with a phenotype very close to
type B.
Table 1 summarizes the key demographic data, and clinical
characteristics, as well as the results of mutation analysis. The
36 patients came from 29 families with their roots in 13 different
countries. THD is a movement disorder with very early onset: all
type B patients had an age at onset within the first months of life,
and 19 out of 25 (76%) of type A patients presented in the first
year of life. The majority of patients (69%) suffered from type A
THD. While responsiveness to L-dopa was absent (36%), moder-
ate (45%) or good (18%) in the type B patients, it was good in
84% of the type A patients. Table 3 provides further details on the
prevalence of other clinical features as well as the response to
L-dopa treatment in type A and B patients as a group. Most add-
itional clinical features are not unique to either type A or B patients.
Nevertheless, there is a clear predominance of extra features in
type B patients, especially with regard to perinatal abnormalities,
diurnal fluctuations, autonomic disturbances and body length and
weight at presentation. None of the patients in this series had
clinical features suggesting systemic deficiency of catecholamines,
such as abnormalities in the maintenance of blood pressure. These
systemic phenomena were not, however, formally studied.
Type A patients generally showed a beneficial L-dopa response
within the first 2 weeks of treatment, while positive effects in type
B patients always occurred later. Selegiline, an inhibitor of dopa-
mine degradation, as well as the dopamine-agonists bromocriptine
and pramipexole, were prescribed in one type A and five type BT
ab
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patients, with some, although limited, additional effects.
Treatment with L-dopa dramatically improved motor outcome in
type A patients: one patient was lost from follow-up, Patients 17
and 25 remained wheelchair bound, and all others (22 out of 25,
88%) were able to walk independently during follow-up. Type B
patients 26, 28 and 35 finally learned to walk independently,
although the initial response to L-dopa had been less impressive
than in most type A cases. The majority (67%) of type A patients
had normal cognitive capacities during follow-up, while 10 out of
11 (91%) type B patients in our series were mentally retarded.
Two type B patients (cases 29 and 33) died during follow-up due
to infectious and respiratory complications.
Cerebral imaging
Most subjects (29 out of 36) underwent cerebral MRI studies. The
images were not systematically reviewed for the purpose of this
study. Non-specific, mild white matter signal changes and
increased volume of extra-cerebral CSF spaces were reported in
nine patients, while the majority of patients (n= 20) had normal
images. The number of patients with abnormalities on MRI was 4
out of 21 (19%) and 5 out of 8 (63%) in Types A and B patients,
respectively. Importantly, gross structural abnormalities of the
brain and signal changes in the basal ganglia were never observed.
Biochemical findings
Based on the metabolic pathway involved, it can be predicted that
CSF levels of the down-stream metabolites of the dopamine deg-
radation pathway will be low, while the serotonin pathway is not
affected (Fig. 1). Age-dependent reference values for the different
metabolites have been published in detail (Brautigam et al., 1998).
As an example, we give here the reference values (P2.5–P97.5) in
childhood (2–5 years): HVA 384–769 nmol/l, 5HIAA 110–265
nmol/l, MHPG 35–64 nmol/l and HVA/5HIAA ratio 1.8–4.4.
Pre-treatment CSF results were lacking from seven patients
[1–5, 17 (Family 7) and 29 (Family 23)]. Patients 1–5 were initially
clinically diagnosed as having a L-dopa-responsive movement dis-
order in the 1970s, and never underwent lumbar puncture. In
Families 7 and 23, a lumbar puncture was performed in only
one of the two affected siblings. Decreased CSF concentrations
of HVA and MHPG, with decreased HVA/5HIAA ratios were
demonstrated in all patients in whom CSF was analysed (Fig. 2).
To enable comparison of patients of different ages, with different
references values, CSF HVA concentrations and HVA/5HIAA ratios
were expressed as percentage of the lower reference limit (2.5th
percentile) (Brautigam et al., 1998). The mean CSF HVA concen-
tration in type B patients was significantly lower (P50.005) than
in type A patients, namely 8.8% (SD 8.9) and 32.7% (SD 19.8),
respectively. As a group, type B patients also had a significantly
lower (P50.005) mean CSF HVA/5HIAA ratio than type A pa-
tients, namely 5.6 (SD 4.7) and 36.7 (SD 18.9), respectively. After
ranking the patients in order of age of onset of the disease (as in
Table 1), we were able to show a positive correlation between age
of onset and CSF HVA concentrations as well as HVA/5HIAA ratio
(Fig. 3). Urinary concentrations of catecholamines and theirT
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degradation products were available in a minority of the patients
(data not shown) and were generally found to be non-informative.
Mutation analysis
We identified 24 different TH gene mutations (Tables 1 and 4;
Fig. 4), located in the promoter sequence, exons 3, 5–14, and in
intron 11. Six mutations were not reported previously. The novel
c.1375C4T mutation was predicted to lead to a stop codon
(p.Gln459X). The other five novel mutations (c.620G4A,
c.680A4G, c.721G4A, c.776A4G and c.1181T4C) were all con-
sidered pathogenic since they were (i) not encountered in 200
control alleles; (ii) not reported as polymorphisms in databases
and the literature (Haavik et al., 2008); and (iii) affecting amino
acids within the tyrosine hydroxylase protein that are highly con-
served among various species. Additionally, the program SIFT
(Sorting Intolerant From Tolerant) (Ng and Henikoff, 2001) pre-
dicted ‘not tolerated’, i.e. a deleterious effect for all five
mutations.
The total number of mutated alleles reported in THD is 100
(Table 4). Five out of these 100 alleles harboured (four different)
mutations that lead to protein truncation [c.295delC, c.296delT,
p.Arg169X (c.DNA change not reported) and c.1375C4T], while
all other 95 alleles were affected by less deleterious missense mu-
tations. Homozygosity for the common c.698G4A mutation was
found in six type A and three type B patients. Homozygosity for
the c.707T4C mutation occurred in one type A and two type B
patients. Promoter mutations were only encountered in type A
THD with good L-dopa responsiveness.
Discussion
In general, the results of the present study and available data in
the literature are in perfect agreement. In total, reports on 50 THD
patients (from 41 families) are now available in the literature, and
are reviewed in this article. Type A THD (n= 35) is more often
diagnosed than type B THD (n= 15).
Clinical features at presentation
The many different neurological features of THD (hypokinesia,
bradykinesia, rigidity, dystonia, chorea, tremor, oculogyric crises,
ptosis and hypersalivation, among others) are caused by cerebral
Box 1. THD type A: ‘Progressive extrapyramidal movement disorder (hypokinetic-rigid syndrome with dystonia) with onset in infancy or
childhood’
These patients are born after uncomplicated pregnancies and develop normally during the first months of life. In rather exceptional cases
(including the first patients described with THD), psychomotor development is even normal or only slightly delayed during the first 2 to 5 years
of life (Castaigne et al., 1971; Rondot and Ziegler, 1983; Rondot et al., 1992). Thereafter, however, progressive motor signs appear. Affected
individuals become hypokinetic and rigid, and dystonia develops. In early stages, generally only one leg is involved, but with time both legs and
also the arms, trunk, face and oropharyngeal musculature become affected. Initial complaints thus encompass abnormal posturing and walking
difficulties, or frequent falls in those who already learned to walk before onset of symptoms. These children become wheelchair bound within
some years.
Most patients with this type A THD are younger than those described above. In these infants, hypokinesia, bradykinesia and rigidity may
dominate the neurological picture while dystonia tends to be less prominent. Initial motor symptoms are generally symmetric and involve arms
as well as legs. The ability to walk is not achieved unless children are treated. Severity of dystonia may fluctuate during the day (generally worse
in the afternoon), but can also fluctuate within days, giving the impression of a paroxysmal dystonia especially in the early stages of the disease.
Mild, non-progressive mental retardation can be found in patients with relatively early onset of motor symptoms, while cognitive functions
appear unaffected in patients who develop symptoms after the first year of life. Besides the hypokinetic-rigid syndrome with dystonia, other
features like tremor, chorea, oculogyric crises and ptosis, as well as behavioural or autonomic disturbances are absent or—if present—are found
as a mild feature and in a minority of patients.
In almost all patients with type A THD, treatment with L-dopa results in an excellent response, sometimes even a miraculous improvement of
the neurological condition. During follow-up, all patients continue to be asymptomatic or display only mild motor or cognitive impairment while
on a low dose of L-dopa. They show no evidence of progressive disease, and tolerate L-dopa well during many years. Extensive, very readable
clinical descriptions of type A THD were, for example, provided by Castaigne et al. (1971), Rondot and Ziegler, (1983), Rondot et al. (1992), de
Rijk-Van Andel et al. (2000) and Schiller et al. (2004).
Box 2. THD type B: ‘Complex encephalopathy with onset in the neonatal period or early infancy’
Immediately after birth, or after a symptom-free interval of only weeks, these patients rapidly develop a complex disorder. In most patients, the
presenting signs are initially contributed to their complicated perinatal history, which makes estimation of age of onset difficult (Table 1; Patients
29–34). The initial signs may differ between infants, but they all develop a varied neurological disorder that generally includes marked
hypokinesia, bradykinesia and hypotonia, mixed with focal or generalized dystonic features and (often excessive) jerky movements like
tremor and myoclonus, and that can also encompass bilateral ptosis and oculogyric crises. Diurnal fluctuation of symptoms may be present
to a minor degree but is generally absent. However, especially in the most severely affected infants dystonic crises occur within regular intervals
of 4–5 days. Mental retardation is generally present, but—as far as can be judged in these severely handicapped children—cognitive functions
seem stable over time. Autonomic functions are often disturbed, especially during periods of dystonia or so-called ‘lethargy-irritability crises’,
leading to excessive drooling, sweating, body temperature instability and marked periods of ‘pyrexia of unknown origin’. True epileptic seizures
and non-epileptic paroxysms may further complicate the clinical picture. L-dopa treatment does not improve all signs equally, and it may take
months before all effects of treatment become clear. Hypersensitivity to L-dopa is an important management problem in many of these patients,
necessitating (extremely) low L-dopa doses at start, divided over four to six doses per day, and only increased over periods of weeks or months.
Compared to type A THD, prognosis with regard to final outcome is worse for motor as well as cognitive functions. Very readable case histories
and videotapes have been provided on patients with this type B phenotype, for example by Surtees and Clayton (1998), de Lonlay et al. (2000),
Hoffmann et al. (2003) and Zafeiriou et al. (2009).
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dopamine and norepinephrine deficiency, as nicely explained and
discussed previously (Grattan-Smith et al., 2002). THD leads to
symptoms early in life, generally in infancy, but sometimes as
early as the neonatal period. Presentation in childhood was very
rare, and no patients identified to date have presented in adoles-
cence or adulthood.
Since THD is rare and its features overlap with many other
neurological disorders, the diagnosis will generally not be made
Table 3 Prevalence of additional clinical features and response to treatment in type A and B patients as a group
Clinical data Type A Type B P-value
Sex, pregnancy, delivery, neonatal period n= 25 n= 11
Male/female 12/13 8/3 N.S.
Preterm birth (537 weeks) 0 4 50.01
Foetal distress (meconium, heart rate abnormalities) 0 6 50.01
Perinatal asphyxia 0 3 50.05
Presenting symptoms/signs n= 25 n= 11
Age at onset 2 month–5 years Neonatal–3 months
Age at onset412 months 6 0 N.S.
Diurnal fluctuation 2 5 50.05
Oculogyric crisis 8 6 N.S.
Ptosis 8 5 N.S.
Autonomic disturbances 3 6 50.05
Lethargy-irritability crises 3 4 N.S.
Sleep disturbances 3 3 N.S.
Seizures 0 2 N.S.
Length52SD 1 4 50.05
Weight52SD 0 3 50.05
Head circumference52SD 3 4 N.S.
Follow-up with medication n= 24 n= 11
Age at start L-dopa 6 months–15 years 6 months–7 years
Chronic L-dopa dose (mg/kg/dy) 3.0–10 0.5–20
L-dopa response: good/moderate/none 21/2/1 2/5/4
L-dopa response: within 1 week/within 2 weeks/after 2 weeks 12/2/9 0/0/7
Selegeline trial 1 5
Effects of selegiline Positive Positive but limited
Other drugs (dopamine agonists) tried None Bromocriptine, pramipexole
Long term follow-up n= 24 n= 11
Mental retardation (IQ570)a 8 10 50.01
Independent walking 22 3 50.001
Died 0 2 N.S.
The differences in the occurrence of clinical features in the two patient categories were studied by using Fisher’s exact test. N.S. = not significant.
a See ‘Discussion’ section for details.
Figure 2 Concentrations of HVA (left panel) and MHPG (middle panel), and HVA/5HIAA ratio (right panel) in CSF of patients with THD
at diagnosis (i.e. without treatment) according to THD subtype. Concentrations are given in percentage of the lower reference limit (2.5th
percentile) in controls (see text). For comparisons between the two groups the Student’s t-test was used. ***P50.005.
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on clinical grounds alone. The differential diagnosis of THD in
neonates or very young infants with type B presentation initially
encompasses a long list of progressive as well as stable, hereditary
as well as acquired disorders. Type B THD is often accompanied
by perinatal complications (Table 3), which may further distract
the attention in the direction of common infectious or
hypoxic-ischaemic encephalopathies. Type B THD can also mimic
genetic disorders like catastrophic epileptic encephalopathies or
mitochondrial disorders. Only extensive work-up, including cere-
bral imaging and screening for inborn errors of metabolism,
including CSF analysis, will lead to the correct diagnosis. In type
A patients on the other end of the spectrum, the children with
‘parkinsonian’ features and L-dopa-responsive dystonia, clinical
recognition of the diagnosis might be easier. Importantly, THD
with a relatively mild course can strongly mimic cerebral palsy,
which may lead to serious diagnostic delay. Besides cerebral
palsy, the differential diagnosis of ‘juvenile parkinsonism’ also in-
cludes various other acquired as well as genetic disorders, among
which GTP cyclohydrolase deficiency and other defects (like
sepiapterine reductase deficiency) in the synthesis of the tyrosine
hydroxylase co-factor tetrahydrobiopterin (BH4) (Muller et al.,
1998; Albanese et al., 2006; Tarsy and Simon, 2006; Muller,
2009). The lack of abnormalities on cerebral imaging studies and
a marked responsiveness to L-dopa are clues to the disorders of
neurotransmitter biosynthesis as a group.
In GTP cyclohydrolase deficiency, the most common defect of
tetrahydrobiopterin biosynthesis, diurnal fluctuation of dystonia,
can be a prominent hallmark. Both THD and GTP cyclohydrolase
deficiency are considered L-dopa-responsive dystonias, and have
been named Segawa syndrome and DYT5 in the past (see
‘Introduction’) (Muller et al., 1998; Albanese et al., 2006; Tarsy
and Simon, 2006; Muller, 2009). THD, however, is generally more
severe and characterized by an earlier onset of symptoms.
Furthermore, the CSF profile of neurotransmitter and pterin
metabolites discriminates between the two disorders. It has
recently been proposed to designate these conditions into GTP
cyclohydrolase deficiency and THD ‘dystonia 5a’ and ‘dystonia
5b’, respectively, illustrating their clinical and biochemical relation-
ship and reflecting their different molecular basis (Muller et al.,
1998).
Figure 3 HVA concentration (left panel) and HVA/5HIAA ratio (right panel) concentrations in CSF of THD patients at diagnosis
(i.e. without treatment), in relation to age at onset of disease. Concentrations are given in percentage of the lower reference limit
(2.5th percentile) in controls. Regression coefficients are: HVA r2= 0.52 (P50.0001), HVA/5HIAA ratio r2= 0.66 (P50.0001).
Figure 4 Overview of all known pathogenic mutations in the TH gene. The cyclic adenosine monophosphate response element of the TH
promotor resides between residues 67 and 74 upstream of the ATG initiation codon.
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Dopamine plays an important regulatory role in the
neuro-endocrine system. Since dopamine suppresses the release
of prolactin, THD may lead to hyperprolactinaemia. Indeed,
serum prolactin may be increased in THD. In the literature, one
patient with THD has been described who presented with galac-
torrhoea due to hyperprolactinaemia before the neurological
features appeared (Yeung et al., 2006). Dopamine is also known
to play an important role in growth hormone secretion.
Nevertheless, height and pubertal development are generally
normal in THD.
Treatment and clinical course
The natural course of THD is—in sensu strictu—unknown.
However, the observations in all patients reported here and in
the literature indicate that the severe neurological features will
never reverse as long as patients are not treated properly.
Since THD leads to dopamine deficiency in the CNS, treatment
with L-dopa is by far the strategy of first choice. In fact, the
lacking metabolite can simply be supplemented (Fig. 1). Drugs
containing L-dopa generally also contain a peripheral L-dopa de-
carboxylase inhibitor (benserazide or carbidopa) to prevent loss of
L-dopa in the circulation. Without further specification, we write
‘treatment with L-dopa’, meaning L-dopa combined with a decarb-
oxylase inhibitor.
L-dopa dosages commonly used in paediatric neurology range
from 3 to 10 mg/kg bodyweight per day, given in three doses.
Although L-dopa-responsive THD patients were usually treated
with an ongoing L-dopa dose in this range, many types A and B
patients started with lower doses, tolerating only very gradual in-
creases in dosage over weeks or even months (see below). Type B
patients especially were often extremely sensitive to L-dopa. This
hypersensitivity necessitated initial dosages below 0.5 mg/kg
bodyweight per day, in four (or even six) divided doses, and
impeded some patients from being treated with L-dopa at all
(Brautigam et al., 1999; de Lonlay et al., 2000; Dionisi-Vici
et al., 2000; Janssen et al., 2000; Haussler et al., 2001;
Grattan-Smith et al., 2002; Hoffmann et al., 2003; Zafeiriou
et al., 2009).
Alternatively and in addition to L-dopa, THD patients can ra-
tionally be treated with inhibitors of dopamine degradation like
selegiline, assuming that some dopamine is still formed in tyrosine
hydroxylase-deficient neurons. Selegiline as well as dopamine
agonists, anticholinergic drugs and benzodiazepines available for
the treatment of dystonia (Albanese et al., 2006; Tarsy and Simon,
2006) were, however, hardly ever used in this series.
Patients who tolerated L-dopa well generally showed a good or
at least moderate response with dramatic improvement of move-
ments due to disappearance of hypokinesia, tremor, rigidity and
dystonia, and subsequent impressive gain in motor functions.
Children who had been in a wheelchair for years started to walk
again. Good responders generally also responded early (Table 3).
These patients only developed L-dopa induced dyskinesia when
dosages were increased too quickly or in too great increments.
To date, only one subject (Patient 23), developed dyskinesia prob-
ably as the consequence of the long-term, i.e. 13 year, treatment
with L-dopa. All others tolerated L-dopa very well and remained
without serious side effects after more than one (Cases 6, 9, 10,
13, 14, 16, 22, 24, 25, 27, 31) or even two or three (Cases 1–5)
decades of treatment. In a limited number of L-dopa-responsive
THD patients, lumbar punctures were performed to monitor treat-
ment effects at the biochemical level. In those cases, clinical re-
sponses were good irrespective to the fact that HVA never
reached normal levels.
Despite appropriate treatment, long-term cognitive develop-
ment was subnormal in many patients with THD. We did not
systematically study cognitive profiles in this series but based on
available test reports, school performance, social functioning and
Table 4 Mutations in the tyrosine hydroxylase gene that
lead to THD
Number Exon Mutation Protein
change
Number of
alleles
affected
1 Promotor c.71C4T 3
2 Promotor c.70G4A 9
3 Promotor c.69T4A 2
4 3 c.295delC p.Leu99fs 1
5 3 c.296delT p.Leu99fs 1
6 3 n.r. p.Arg169X 2
7 5 c.614T4C p.Leu205Pro 2
8 5 c.620G`A p.Cys207Tyr 1
9 6 c.680A`G p.Asp227Gly 1
10 6 c.698G4A p.Arg233His 28
11 6 c.707T4C p.Leu236Pro 6
12 6 c.721G`A p.Ala241Thr 2
13 6 c.736C4T p.His246Tyr 1
14 7 c.739G4A p.Gly247Ser 1
15 7 c.776A`G p.Glu259Gly 1
16 8 c.826A4C p.Thr276Pro 1
17 8 c.901C4G p.Pro301Ala 2
18 8 c.926T4C p.Phe309Ser 2
19 9 c.941C4T p.Thr314Met 1
20 9 c.956G4C p.Arg319Pro 1
21 9 c.982C4T p.Arg328Trp 1
22 9 c.1010G4A p.Arg337His 2
23 10 c.1076G4T p.Cys359Phe 2
24 10 c.1125C4G p.Phe375Leu 1
25 10 c.1127C4T p.Ala376Val 2
26 11 c.1141C4A p.Gln381Lys 4
27 11 c.1159C4A p.Leu387Met 1
28 11 c.1181T`C p.Ile394Thr 2
29 11 c.1196C4T p.Thr399Met 1
30 Intron 11 c.1198–24T4A p.? 2
31 12 c.1240G4A p.Gly414Arg 2
32 13 c.1375C`T p.Gln459X 1
33 13 c.1399A4G p.Ser467Gly 1
34 14 c.1475C4T p.Pro492Leu 2
35 14 c.1481C4T p.Thr494Met 2
36 14 c.1493A4G p.Asp498Gly 4
37 14 c.1529T4A p.Leu510Gln 2
This table includes all mutations reported to date in THD, and six novel mutations
(in bold) reported in this article. In case of affected sib-pairs, both patients are
included. The total number of mutated alleles is 100. For all mutations: see
Tables 1 (our series of patients) and 3 (all patients reported by others). n.r. = not
reported.
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clinical impression by experienced neurologists, it was concluded
that mild to moderate mental retardation occurred in 33 and 91%
of Types A and B patients, respectively (Table 3). In none of the
patients we encountered signs of cognitive decline under
treatment.
Based on shared experiences, but impossible to prove due to the
low number of patients, we think that early diagnosis and treat-
ment of THD improves the final outcome with regard to motor as
well as cognitive functions. On the other hand, it has extensively
been demonstrated in animal studies that dopamine plays a vital
role in foetal brain development (Zhou et al., 1995; Araki et al.,
2007). Dopamine deficiency might therefore cause, already before
birth, irreversible structural brain abnormalities at the microscopic
level and leading to mental retardation.
Taking all data together, THD can best be treated with an initial
L-dopa dose of 0.5–1 (for type B patients) to 3 (for type A pa-
tients) mg/kg bodyweight per day, divided over three or four
doses. When tolerated well, the dose can slowly be increased
until the desired clinical response is observed or the occurrence
of adverse effects forces dose reduction. It should be kept in
mind that some patients respond only in the course of months:
one should thus wait long enough to see the final effects in ap-
parent moderate or non-responders. We think that type B patients
with extreme L-dopa hypersensitivity might be ideal candidates for
continuous duodenal administration of a soluble formulation of
L-dopa (duodopa), although we did not encounter this approach
in our series and the literature.
Biochemistry and genetics
Cathecholamine biosynthesis was long thought to occur only in
specific neuronal cell populations in the CNS, sympathetic periph-
eral nervous system, adrenal glands and the kidneys. Interestingly,
however, the presence of the tyrosine hydroxylase protein, its
mRNA and its enzymatic activity, have been demonstrated in
other non-neuronal tissues capable of catecholamine biosynthesis,
such as lymphoid tissues, exocrine pancreas and the gastrointes-
tinal tract (Mezey et al., 1996; Eisenhofer et al., 1997). Human
THD leads to a neurological disorder, apparently leaving the other
organs unaffected. An explanation for this observation might be
that the brain is the most vulnerable organ, already severely
affected by relatively minor changes in the TH gene (see
below). A second explanation might be found in other enzymes,
expressed in non-neuronal tissues, which can hydroxylate tyrosine.
Tyrosinase (E.C. 1.14.18.1), for example, is expressed in the
epidermis and plays a crucial role in melanin biosynthesis from
tyrosine (Rios et al., 1999). In humans, tyrosinase deficiency
leads to oculocutaneous albinism type 1 (OMIM 606933)
(Oetting et al., 2003). In mice, tyrosinase substantially contributes
to peripheral, tyrosine hydroxylase-independent dopamine produc-
tion (Eisenhofer et al., 2003).
The biochemical diagnosis of THD would ideally rely on direct
measurement of enzyme activity in tissue samples, blood cells or
cultured fibroblasts. Since it was traditionally thought that tyro-
sine hydroxylase was only expressed in tissues that would not
be available for enzymatic analyses, we and others have
always relied on CSF metabolites (Fig. 1) and TH gene
mutation analysis to diagnose THD. The collected data of the
large series of patients described here clearly demonstrate that
the most severely affected patients have the lowest concentrations
of neurotransmitter metabolites in CSF (Fig. 3). The HVA concen-
tration and HVA/5HIAA ratio in CSF showed overlap between
Types A and B patients, however this overlap was only minor
for the HVA/5HIAA ratio (Fig. 2). These parameters (especially
the HVA/5HIAA ratio in CSF), most probably reflecting the
degree of residual tyrosine hydroxylase activity in the brain, may
thus be used to predict L-dopa responsiveness and overall
outcome.
Measurements of phenylalanine and tyrosine in body fluids, and
urinary concentrations of catecholamines, HVA and MHPG, are
non-informative in patients with THD (Brautigam et al., 1998;
Wevers et al., 1999; Hoffmann et al., 2003). The surprisingly
often normal urinary dopamine excretion in THD is hypothetically
attributed to residual tyrosine hydroxylase enzyme activity in per-
ipheral non-neuronal tissues or alternative enzymes with the cap-
acity to hydroxylate tyrosine, as discussed above. The fact that
profound cerebral dopamine deficiency due to defective dopamine
biosynthesis can be accompanied by normal urinary dopamine ex-
cretion makes analysis of urine unreliable, even potentially mis-
leading, in the diagnostic work-up for dopamine biosynthesis
disorders.
The human TH gene (mRNA type 1) contains 14 exons with an
open reading frame of 1491 bp encoding for a protein with 497
amino acids that is highly conserved among various species
(Nagatsu and Ichinose, 1991) Tables 1, 2 and 4, and Fig. 4,
give an overview of the 37 different TH mutations in THD pa-
tients. Out of 100 alleles, 95 were affected by missense mutations
leading to amino acid substitutions in the protein with subsequent
partial loss of enzyme activity. The pathogenic effects of some
missense mutations on the protein have been confirmed,
(Ludecke et al., 1995, 1996; Knappskog et al., 1995; Royo
et al., 2005; Haavik et al., 2008) but most can only be designated
pathogenic based on indirect evidence. Interestingly, we and
others have recently identified pathogenic mutations in the pro-
moter region of the TH gene as a rare underlying genetic mech-
anism (Ribases et al., 2007; Verbeek et al., 2007). A founder
effect has been described for the c.698G4A mutation in the
Dutch population (van den Heuvel et al., 1998). Except for this
and two other mutations (c.70G4A and c.707T4C), almost all
other pathogenic changes in the TH gene are so-called ‘private’
mutations (Table 4). Based on the latter finding, it can be ex-
pected that THD occurs in all parts of the world, irrespective of
the fact that up to now most patients were diagnosed in Western
Europe.
The relatively high number of patients in this paper allows us to
discuss possible genotype–phenotype correlations in THD. Only
five patients, from four families, harboured deleterious mutations
that lead to protein truncation: namely c.295delC and c.296delT,
which both lead to p.Leu99fs; p.Arg169X (the c.DNA change was
not reported in the two affected siblings); and c.1375C4T, which
causes p.Gln459X. Heterozygosity for each of these mutations was
found in type A as well as type B patients. Until now, no patient
has been reported with homozygosity or compound heterozygos-
ity for two truncating TH mutations. This observation most
1820 | Brain 2010: 133; 1810–1822 M. A. Willemsen et al.
probably indicates that complete loss of tyrosine hydroxylase ac-
tivity is incompatible with human life, comparable with the find-
ings in knockout mice (Zhou et al., 1995). Homozygosity for the
common c.698G4A mutation and homozygosity for the c.707T4C
mutation was found in both THD phenotypes (Table 1), leaving
these genotypes without predictive value with regard to THD
phenotype. Importantly, however, all patients carrying at least
one promoter mutation (n= 8, Tables 1 and 2) suffered from
type A THD with good L-dopa responsiveness. As discussed pre-
viously, reduced TH gene transcription apparently leaves signifi-
cant residual tyrosine hydroxylase enzyme activity, likely
corresponding to a relatively mild type A phenotype (Ribases
et al., 2007; Verbeek et al., 2007).
The differential diagnosis in children and adults with movement
disorders is essentially different. This explains the remarkable di-
versity in the diagnostic approach depending on the patient’s age.
Adult patients with dystonia can be investigated at the genetic
level after dedicated neurological classification (Muller et al.,
1998; Albanese et al., 2006; Tarsy and Simon, 2006; Wu et al.,
2008; Clot et al., 2009; Muller, 2009), while children often have
to be exposed to more extensive and invasive diagnostic procedures
to illuminate the underlying cause of their disorder (Assmann et al.,
2003). In contrast to what is advocated for adult patients, we
strongly advise performance of a lumbar puncture in children with
otherwise unexplained (simple and complex) movement disorders,
to diagnose or rule out potentially treatable conditions like THD.
In conclusion, THD is a severe but often very treatable
neurometabolic disorder resulting from cerebral catecholamine
deficiency. The diagnosis of THD relies on clinical suspicion and
the analysis of CSF metabolites. Importantly, the CSF concentra-
tion of HVA and HVA/5HIAA ratio correlate with the severity of
the clinical phenotype. THD can be proven by demonstrating
mutations in the TH gene or its promoter region. The disorder is
almost exclusively caused by missense mutations, suggesting that
mutations with more deleterious effects on the protein will be
incompatible with life. Genotype–phenotype correlations do not
exist for the common c.698G4A and c.707T4C mutations.
Carriership of at least one promotor mutation, however, apparent-
ly predicts type A THD. Most patients with THD, but not all, can
successfully be treated with L-dopa.
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